AMEXDRUG CORPORATION SECURES POTENTIAL FOR $9 MILLION IN PRODUCTION CAPACITY

Amexdrug Corporation (OTC BB: AXRX), who recently announced the completion of the Dermagen Inc. acquisition, filed SEC Form 8-K which, among other things, confirmed the closure of the company's recent acquisition in a cash deal. According to terms of the agreement, Dermagen will now become an operating subsidiary of Amexdrug, adding a significant manufacturing component to Amexdrug's structure, as well as extensive expertise in numerous phases of private label contract packaging.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=98278)